KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Interest Expenses (2016 - 2026)

Esperion Therapeutics filings provide 7 years of Interest Expenses readings, the most recent being $22.6 million for Q4 2025.

  • On a quarterly basis, Interest Expenses fell 8.2% to $22.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $84.6 million, a 25.37% increase, with the full-year FY2025 number at $84.6 million, up 42.79% from a year prior.
  • Interest Expenses hit $22.6 million in Q4 2025 for Esperion Therapeutics, up from $22.1 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $24.7 million in Q4 2024 to a low of $8.1 million in Q1 2021.
  • Median Interest Expenses over the past 5 years was $14.4 million (2022), compared with a mean of $15.7 million.
  • Biggest five-year swings in Interest Expenses: surged 177.07% in 2021 and later fell 8.2% in 2025.
  • Esperion Therapeutics' Interest Expenses stood at $13.4 million in 2021, then grew by 6.69% to $14.3 million in 2022, then grew by 5.08% to $15.1 million in 2023, then skyrocketed by 63.76% to $24.7 million in 2024, then decreased by 8.2% to $22.6 million in 2025.
  • The last three reported values for Interest Expenses were $22.6 million (Q4 2025), $22.1 million (Q3 2025), and $20.5 million (Q2 2025) per Business Quant data.